According to the researchers, few treatments have been able to reduce the thrombotic burden in patients with polycythemia vera (PV) and essential thrombocytopenia (ET), and progress on this front has been hindered by a lack of studies designed to assess a treatment’s impact on thrombotic events.
Thrombosis is a major contributor to morbidity and mortality in patients with polycythemia vera (PV) and essential thrombocytopenia (ET) but there are challenges with accurately assessing a novel therapy’s effectiveness at reducing thrombotic events. A recent report offers guidance for future research.
According to the authors, few treatments have been able to reduce the thrombotic burden in patients with PV and ET, and progress on this front has been hindered by a lack of studies designed to assess a treatment’s impact on thrombotic events. In studies that are designed as primary prevention trials of thrombosis-related endpoints in the 2 diseases, they are met with several challenges, including low accrual and lack of feasibility to further accrue.
“Despite thrombosis accounting for the majority of morbidity and mortality in PV and ET, clinical research up to this point has been largely unregimented when it comes to evaluating the impact of therapeutic strategies on thrombosis,” explained the researchers, adding, “While many disease-specific limitations exist to account for the lack of attention toward thrombosis reduction, we believe these obstacles can be overcome with surrogate endpoint and biomarker validation studies, in addition to uniform clinical trial design.”
A surrogate endpoint touted by the researchers is hematocrit control <45%, based on a study that assessed 3 different aspirin regiments in ET. The study’s primary endpoint was TxA2, an unproven endpoint. According to the researchers, the approach highlighted measurable differences at 2 weeks rather than the traditional years it would normally take for outcomes such as thrombosis to occur.
The researchers note that there is difficulty in knowing if a surrogate endpoint is meaningful in all populations, and as a result, they urge that the relationship between a surrogate endpoint and the endpoint of interest should be well-established.
“Future studies should be aimed at validating surrogate endpoints for predicting thrombosis. One such method is trial-level validation, where the change in an endpoint is plotted against the change in a well-defined endpoint (i.e. thrombosis),” suggested the researchers. “The strength of this association is then measured by regression analysis. This strategy requires multiple trials that measure the same biomarker and endpoints.”
Non-inferiority trial designs also may play a potential role, say the researchers, who note that this type of design requires the consideration of the chosen non-inferiority margin that is sensitive to the assumed effects of a novel treatment relative to past effectiveness of the comparator treatment.
Reference
Tremblay D, Kosiorek, Dueck A, Hoffman R. Evaluation of therapeutic strategies to reduce the number of thrombotic events in patients with polycythemia vera and essential thrombocythemia. Front Oncol. Published online February 16, 2021. doi:10.3389/fonc.2020.636675
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Prediction Model Identified Risk Factors for ED Visits in Patients With Lung Cancer
December 7th 2023A risk prediction model that was based on machine learning could help to make resource utilization more efficient by correctly predicting emergency department (ED) visits in patients with lung cancer.
Read More
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More